alexander disease diagnosed in an obstetrics patient a case report and review of the literature

Original title: “Alexander Disease Diagnosed in an Obstetrics Patient: A Case Report and Review of the Literature.”

photobiomodulation ameliorates alexander disease through ampk mtor mediated mitophagy

Original title: “Photobiomodulation Ameliorates Alexander Disease Through AMPK/mTOR-Mediated Mitophagy.”

September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.

Original title: “Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease”

cellular models for studying alexander disease functional analysis of primary rat astrocytes

Original title: “Cellular Models for Studying Alexander Disease: Functional Analysis of Primary Rat Astrocytes.”

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Original title: “Ionis’ rare neurology drug approved; Pfizer inks an ADC deal”

cognitive impairment in adult alexander disease

Original title: “Cognitive impairment in adult Alexander disease.”

demonstrating clinical and radiological variability of adult onset alexander disease in three siblings

Original title: “Demonstrating clinical and radiological variability of adult-onset Alexander disease in three siblings.”